Nutex Health: A High-Risk, High-Reward Play For Speculative Investors

Summary Nutex Health has surged 134% since April, driven by its out-of-network micro-hospital model and expanding margins. It has staged a turnaround in 2026, driven by strong EPS growth after years of struggle. The company leverages the No Surprises Act’s arbitration process to sustain margins against insurer underpayment, making dispute resolution central to its current business. Key risks include regulatory changes, insurer resistance, reliance on arbitration, and declining revenue per patient. Nutex is a buy for healthcare investors looking to speculate on the stock's high upside potential. M. Suhail/iStock Editorial via Getty Images Nutex Health ( NUTX ) has rallied close to 100% since the beginning of April 2026, as the market has been pleased with the company's margin and EPS growth turnaround this year. The company operates "out-of-network" micro-hospitals This article was written by Star Investments 7.42K Followers Follow I have been a Merchant Seaman that has traveled the world for over 30 years. Within the last 15 years, I developed a very intense interest in investing. I learned a lot of what I know about investing from The MF. Also because I have a engineering background, I often tend to gravitate to Tech stocks Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.